research use only

Monomethyl Fumarate GPR agonist

Name: Monomethyl Fumarate
Brand: Selleck Chemicals
SKU: S6889
Availability: InStock
Rating: 5 (2 reviews)

Cat.No.S6889

Monomethyl Fumarate (MMF, Monomethylfumarate, Fumaric acid monomethyl ester, Methyl hydrogen fumarate), the active metabolite of the psoriasis drug Fumaderm, is a potent GPR109A agonist. This compound prevents major dysfunctions associated with neurodegenerative diseases: oxidative stress, mitochondrial dysfunction, apoptosis and autophagy.

Chemical Structure

Molecular Weight: 130.10

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.59%

99.59

Related Targets	Adrenergic Receptor AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras GluR Prostaglandin Receptor CXCR Adenosine Receptor P2 Receptor CCR Angiotensin Receptor Hedgehog/Smoothened S1P Receptor PKA Cannabinoid Receptor cAMP Glucagon Receptor SGLT Opioid Receptor Sigma Receptor PAR Endothelin Receptor LTR Neurokinin Receptor Guanylate Cyclase PKG LPA Receptor OX Receptor
Related Products	Fasiglifam(TAK-875) Hemihydrate GW9508 ONC212 AH7614 JMS-17-2 3-chloro-5-hydroxybenzoic Acid AZD1981 GSK1292263 6-OAU GSK137647A TC-O 9311 APD668 NF-56-EJ40 [Pyr1]-Apelin-13 DC260126 Kisspeptin-10 (human) Azelaprag AS1269574 NOX-6-18（GPR132-B-160） SNAP94847 hydrochloride DJ-V-159 O-1602 Anti-GPR49 / LGR5 (BNC101) Anti-GPRC5D Petosemtamab (Anti-EGFR / LGR5) APD597 Anti-GPR64 / ADGRG2 TC-G-1008 (GPR39-C3) GPR84 antagonist 8 7α,25-Dihydroxycholesterol

Chemical Information, Storage & Stability

Molecular Weight	130.10	Formula	C₅H₆O₄	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	2756-87-8	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	MMF, Monomethylfumarate, Fumaric acid monomethyl ester, Methyl hydrogen fumarate			Smiles	COC(=O)\C=C\C(O)=O

Solubility

In vitro
Batch:

DMSO : 26 mg/mL (199.84 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 26 mg/mL

Water : 20 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	GPR109A ^[1]
References	[1] https://pubmed.ncbi.nlm.nih.gov/18722346/ [2] https://pubmed.ncbi.nlm.nih.gov/31344443/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05858970	Not yet recruiting	Optical Biopsy\|Colonic Dysplasia\|Diagnostic Accuracy	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	April 1 2024	--
NCT06066957	Recruiting	Cytomegalovirus Infections\|Transplant-Related Disorder	University of Pennsylvania\|Merck Sharp & Dohme LLC	April 4 2024	Phase 2
NCT05538208	Recruiting	Lupus Nephritis	Children''s Hospital Medical Center Cincinnati\|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)\|Genentech Inc.	January 2024	Phase 2
NCT04776473	Recruiting	Intra-articular Fracture of the Mandibular Condyle	Assistance Publique - Hôpitaux de Paris	May 3 2023	Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):